Corvus Pharmaceuticals Inc (NASDAQ:CRVS) has been given an average rating of “Buy” by the seven brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $14.00.

CRVS has been the subject of a number of research analyst reports. BidaskClub raised shares of Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. Credit Suisse Group raised shares of Corvus Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price target for the stock from $11.00 to $15.00 in a research note on Wednesday, August 15th. ValuEngine lowered shares of Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, June 18th. Jefferies Financial Group initiated coverage on shares of Corvus Pharmaceuticals in a research note on Tuesday, June 5th. They issued a “buy” rating and a $17.00 price target for the company. Finally, Zacks Investment Research lowered shares of Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, June 13th.

Several large investors have recently modified their holdings of CRVS. Deutsche Bank AG lifted its stake in shares of Corvus Pharmaceuticals by 118.1% in the 4th quarter. Deutsche Bank AG now owns 19,058 shares of the company’s stock worth $196,000 after acquiring an additional 10,320 shares during the period. BlackRock Inc. lifted its stake in shares of Corvus Pharmaceuticals by 10.1% in the 1st quarter. BlackRock Inc. now owns 737,118 shares of the company’s stock worth $8,499,000 after acquiring an additional 67,461 shares during the period. Sphera Funds Management LTD. lifted its stake in shares of Corvus Pharmaceuticals by 45.2% in the 1st quarter. Sphera Funds Management LTD. now owns 321,430 shares of the company’s stock worth $3,706,000 after acquiring an additional 100,000 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Corvus Pharmaceuticals by 112.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 134,436 shares of the company’s stock worth $1,550,000 after acquiring an additional 71,300 shares during the period. Finally, Rock Springs Capital Management LP lifted its stake in shares of Corvus Pharmaceuticals by 36.1% in the 1st quarter. Rock Springs Capital Management LP now owns 575,000 shares of the company’s stock worth $6,630,000 after acquiring an additional 152,400 shares during the period. 88.72% of the stock is owned by institutional investors.

Corvus Pharmaceuticals stock traded down $0.01 during midday trading on Wednesday, reaching $8.85. 60,083 shares of the stock traded hands, compared to its average volume of 96,333. The firm has a market capitalization of $258.69 million, a price-to-earnings ratio of -3.36 and a beta of -1.94. Corvus Pharmaceuticals has a fifty-two week low of $7.42 and a fifty-two week high of $17.30.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its earnings results on Thursday, August 2nd. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.24. research analysts anticipate that Corvus Pharmaceuticals will post -1.98 earnings per share for the current year.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.

Featured Article: Trading Strategy Methods for Individual Investors

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.